S&P 500 cuts losses as Nvidia climbs ahead of results
Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a $1.47 billion market cap biotech company, sold 2,862 shares of common stock on August 12, 2025, at prices ranging from $13.36 to $13.49, for a total value of $38,329. The transaction comes as EWTX shares have gained nearly 10% over the past week, though they remain well below their 52-week high of $38.12. InvestingPro analysis shows the stock is currently trading above its Fair Value.
According to a Form 4 filing with the Securities and Exchange Commission, Donovan also acquired 5,781 shares of common stock upon the exercise of restricted stock units. Additionally, Donovan was granted 28,125 restricted stock units and options to purchase 168,750 shares of common stock. The company maintains strong liquidity with a current ratio of 28.87, and according to InvestingPro, holds more cash than debt on its balance sheet. For comprehensive insider trading analysis and 8 additional key insights about EWTX, explore the full Pro Research Report available on InvestingPro.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025, with a loss of $0.34 per share compared to analysts’ projections of a $0.42 per share loss. The company concluded the quarter with a robust cash position of around $594 million, which supports its ongoing clinical programs. RBC Capital has raised its price target for Edgewise Therapeutics to $49, maintaining an Outperform rating following the company’s earnings report. Raymond James also reiterated a Strong Buy rating with a $46 price target, citing the company’s financial results and corporate updates. Both firms noted that key catalysts, including the EDG-7500 Phase 2 CIRRUS-HCM Part D results, remain on schedule for the fourth quarter of 2025. Earlier data from the trial showed promising efficacy signals, although there were concerns about a potential atrial fibrillation signal in 14% of patients. These developments reflect continued investor interest and confidence in Edgewise’s financial and clinical progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.